Moderate to Severe Plaque Psoriasis Clinical Trials

6 recruitingLast updated: May 21, 2026

There are 6 actively recruiting moderate to severe plaque psoriasis clinical trials across 14 countries. Studies span Phase 3, Not Applicable, Phase 1. Top locations include Fountain Valley, California, United States, Freiburg im Breisgau, Germany, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Moderate to Severe Plaque Psoriasis Trials at a Glance

6 actively recruiting trials for moderate to severe plaque psoriasis are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in Fountain Valley, Freiburg im Breisgau, and Barcelona. Lead sponsors running moderate to severe plaque psoriasis studies include UCB Biopharma SRL, Bristol-Myers Squibb, and First Hospital of China Medical University.

Browse moderate to severe plaque psoriasis trials by phase

About Moderate to Severe Plaque Psoriasis Clinical Trials

Looking for clinical trials for Moderate to Severe Plaque Psoriasis? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Moderate to Severe Plaque Psoriasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Moderate to Severe Plaque Psoriasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL168 enrolled50 locationsNCT06425549
Recruiting
Phase 1

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Hidradenitis SuppurativaPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL20 enrolled12 locationsNCT06888193
Recruiting
Phase 3

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

Psoriatic ArthritisModerate to Severe Plaque Psoriasis
UCB Biopharma SRL90 enrolled16 locationsNCT06506916
Recruiting
Not Applicable

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

Plaque PsoriasisModerate to Severe Plaque Psoriasis
Usynova Pharmaceuticals Ltd.140 enrolled1 locationNCT07234591
Recruiting

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis
First Hospital of China Medical University1,516 enrolled1 locationNCT06696417
Recruiting

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb505 enrolled2 locationsNCT06258668